会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 152. 发明申请
    • LIQUID PHOTOCURABLE COMPOSITIONS
    • 液体光电组合物
    • WO1996028762A1
    • 1996-09-19
    • PCT/GB1996000517
    • 1996-03-06
    • ZENECA LIMITEDPOPAT, Ajay, HaridasLAWSON, John, RobertMCLEAN, Colin, Henry
    • ZENECA LIMITED
    • G03F07/027
    • G03F7/0037G03F7/027
    • A liquid composition comprising: a) 5 to 25 parts of a monomeric aliphatic or cycloaliphatic di(meth)acrylate having a MW of not more than 800; b) 2 to 20 parts of a monomeric poly(meth)acrylate having a functionality of at least 3 and a MW of at least 610; c) 12 to 40 parts of a urethane(meth)acrylate having a functionality of 2 to 4 and a MW of 400 to 10,000; d) 35 to 70 parts of a monomeric or oligomeric di(meth)acrylate based on bisphenol A or bisphenol F; and e) 0.1 to 10 parts of a photoinitiator; wherein all parts are by weight, the total number of parts of a) + b) does not exceed 30 and the total number of parts of a) + b) + c) + d) + e) add up to 100. The compositions are suitable for the stereolighographic production of three-dimensional solid articles such as mechanical parts and models of body parts.
    • 一种液体组合物,其包含:a)5〜25份MW不大于800的单体脂族或脂环族二(甲基)丙烯酸酯; b)2至20份官能度至少为3且MW至少为610的单体聚(甲基)丙烯酸酯; c)12〜40份官能度为2〜4,MW为400〜10,000的氨基甲酸酯(甲基)丙烯酸酯; d)35〜70份基于双酚A或双酚F的单体或低聚二(甲基)丙烯酸酯; 和e)0.1至10份光引发剂; 其中所有部分都是重量比,a)+ b)的部分总数不超过30,a)+ b)+ c)+ d)+ e)的总数量加到100上。组合物 适用于三维固体制品如机械零件和车身部件型号的立体定向生产。
    • 155. 发明申请
    • PROCESS FOR THE PRODUCTION OF 2-(SUBSTITUTED BENZOYL)-1,3 CYCLOHEXANEDIONES
    • 2-(取代苯甲酰基)-1,3环己酮的制备方法
    • WO1996022957A1
    • 1996-08-01
    • PCT/GB1996000081
    • 1996-01-16
    • ZENECA LIMITEDBROWN, Stephen, MartinRAWLINSON, HowardWIFFEN, Jonathan, William
    • ZENECA LIMITED
    • C07C45/54
    • C07C315/04C07C45/54C07C317/24C07C49/792
    • A process for preparing a compound of formula (I), where R , R , R , R , R and R are independently hydrogen or C1-6 alkyl; R is halogen, cyano, NO2, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy or RaS in which Ra is C1-4 alkyl; R , R and R independently are hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, CN, NO2, phenoxy or substituted phenoxy; RbS(O)n Om in which m is 0 or 1, n is 0, 1 or 2 and Rb is C1-4 alkyl, C1-4 haloalkyl, phenyl or benzyl, NHCORc in which Rc is C1-4 alkyl, NRdRe in which Rd and Re independently are hydrogen or C1-4 alkyl; RfC(O)- in which Rf is hydrogen, C1-4 alkyl, C1-4 haloalkyl or C1-4 alkoxy; SO2NRgRh in which Rg and Rh independently are hydrogen or C1-4 alkyl; or any two of R , R and R together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing up to three heteroatoms selected from O, N or S and which may be optionally substituted by C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, =NOC1-4 alkyl, or halogen; which process comprises the rearrangement of a compound of formula (II), where R , R , R , R , R , R , R , R , R and R are as defined in relation to formula (I), in the presence of a base and a polar aprotic solvent characterised in that the process is carried out in a reaction medium substantially free of hydrogen cyanide or cyanide anion.
    • 制备式(I)化合物的方法,其中R 1,R 2,R 3,R 4,R 5和R 6独立地是氢或C 1-6烷基 ; R 7是卤素,氰基,NO 2,C 1-4烷基,C 1-4卤代烷基,C 1-4烷氧基或R a,其中R a是C 1-4烷基; R 8,R 9和R 10独立地是氢,卤素,C 1-4烷基,C 1-4烷氧基,C 1-4卤代烷基,C 1-4卤代烷氧基,CN,NO 2,苯氧基或取代的苯氧基; RbS(O)n Om,其中m为0或1,n为0,1或2,Rb为C1-4烷基,C1-4卤代烷基,苯基或苄基,NHCORc,其中Rc为C1-4烷基,NRdRe为 哪个Rd和Re独立地是氢或C 1-4烷基; RfC(O) - ,其中R f为氢,C 1-4烷基,C 1-4卤代烷基或C 1-4烷氧基; 其中Rg和Rh独立地为氢或C1-4烷基的SO2NRgRh; 或R 8,R 9和R 10中的任何两个与它们所连接的碳原子一起形成含有至多三个选自O,N或S的杂原子的5或6元杂环,并且其中 可以任选地被C 1-4烷基,C 1-4卤代烷基,C 1-4烷氧基,= NOC 1-4烷基或卤素取代; 该方法包括式(II)化合物的重排,其中R 1,R 2,R 3,R 4,R 5,R 6,R 7, 在碱和极性非质子溶剂的存在下,R 8,R 9和R 10如关于式(I)所定义,其特征在于该方法在基本上无反应的反应介质中进行 的氰化氢或氰化物阴离子。
    • 157. 发明申请
    • FIBRONECTIN ADHESION INHIBITORS
    • 纤维素粘合抑制剂
    • WO1996020216A1
    • 1996-07-04
    • PCT/GB1995002992
    • 1995-12-21
    • ZENECA LIMITEDDUTTA, Anand, Swaroop
    • ZENECA LIMITED
    • C07K14/78
    • C07K14/78A61K38/00
    • Cyclic peptides of formula (1) wherein: AA1 is an L or D amino acid selected form Ile and Leu or amino acid analogue thereof; AA2 is an L amino acid selected from Leu or amino acid analogue thereof; AA3 is an L amino acid selected from Asp or amino acid analogue thereof containing a carboxyl group in its side chain; AA4 is an L amino acid selected from Val or amino acid analogue thereof and; LINKER represents a linking moiety for linking N terminus of AA1 to C terminus of AA4 to form a cyclic peptide containing a heterocyclic ring having 17 to 30 members. The cyclic peptides inhibit the interaction of vascular cell adhesion molecule-1 and fibronectin with integrin very late antigen 4 and have therapeutic applications such as in rheumatoid arthritis or multiple sclerosis.
    • 式(1)的环肽,其中:AA1是选自Ile和Leu或其氨基酸类似物的L或D / D氨基酸; AA2是选自Leu或其氨基酸类似物的一种L 氨基酸; AA3是选自Asp或其侧链中具有羧基的氨基酸类似物的L-氨基酸; AA4是选自Val或其氨基酸类似物的L9A氨基酸; LINKER表示将AA1的N末端与AA4的C末端连接的连接部分,形成含有17〜30个成员的杂环的环状肽。 环肽抑制血管细胞粘附分子-1和纤连蛋白与整联蛋白非常晚的抗原4的相互作用,并具有治疗应用,例如类风湿性关节炎或多发性硬化。